ArticleNeurosurgical review2026
Microscopic vs. exoscopic transsphenoidal surgery for rathke's cleft cyst- a retrospective single center study.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroscopic (MTS) or endoscopic transsphenoidal surgeries (ETS) are two main well established approaches for the management of sellar pathologies in contemporary established approaches for the management of sellar pathologies in contemporary neurosurgical practice. Exoscopic transsphenoidal surgery (ExTS), which employs a 4K 3D camera system (Orbeye, Olympus), has recently emerged as a promising alternative; however, its role in the management of Rathke’s cleft cysts (RCC) remains unclear. This study aimed to evaluate the surgical characteristics and clinical outcomes of ExTS in patients with RCC and to compare these results with those achieved using the more widely established microscopic transsphenoidal surgery (MTS) technique.
methodsWe performed a retrospective analysis of electronic medical records of all transsphenoidal operations conducted between July 2013 and May 2022 at the University Medical Center Hamburg-Eppendorf. 125 patients with RCC after a defined type of transsphenoidal surgery were included.
resultsMean operative duration was similar between groups (78.5 ± 21.7 min vs. 73.1 ± 26.7 min, p = 0.20). Complication and recurrence rates did not differ significantly between MTS and ExTS (16.7% vs. 9.7%; p = 0.54). Across learning phases, ExTS showed a greater reduction in operative time (85.5 → 59.8 min; p = 0.047) than MTS (98.2 → 84.6 min; p = 0.128). In the mixed-effects model adjusting for clinical covariates and inter-surgeon variability, surgical technique (ExTS vs. MTS; p = 0.021), age (p = 0.005), previous surgery (p = 0.008), suprasellar cyst location (p = 0.031), and drainage (p = 0.006) were significant predictors of operative duration. A significant Experience × ExTS interaction (p = 0.005) indicated a more pronounced experience-dependent reduction in operative duration for ExTS compared with MTS.
conclusionExTS using a 4K 3D system demonstrated safety and efficacy comparable to the MTS. After adjustment for clinical covariates and inter-surgeon variability, ExTS remained an independent predictor of shorter operative duration and demonstrated a more pronounced independent predictor of shorter operative duration and demonstrated a more pronounced experience-dependent reduction in operative duration for ExTS compared with MTS. These findings support ExTS as a safe and time-efficient alternative for managing RCC. Nevertheless, prospective multicenter studies with long-term follow-up are required to validate these results and further delineate the role of exoscopic system.
Indexed as
Identifiers
41843364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.